Medtronic Stock Hits New 52-Week High (MDT)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Medtronic (NYSE: MDT) hit a new 52-week high Tuesday as it is currently trading at $52.92, above its previous 52-week high of $50.17 with two million shares traded as of 9:35 a.m. ET. Average volume has been 4.2 million shares over the past 30 days.

Medtronic has a market cap of $50.53 billion and is part of the health care sector and health services industry. Shares are up 21.5% year to date as of the close of trading on Monday.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company has a P/E ratio of 15.2, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Medtronic Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

These Stocks Are Showing Reversal Patterns

These Stocks Are Showing Reversal Patterns